Circulation. 2002 Sep 24;106(13):1622-6. Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups. (CURE) Budaj A， Yusuf S， Mehta SR， Fox KA， Tognoni G， Zhao F， Chrolavicius S， Hunt D， Keltai M， Franzosi MG; Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial Investigators. Postgraduate Medical School， Grochowski Hospital Warsaw， Poland.
BACKGROUND: The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial demonstrated that clopidogrel， given early and continued long term， was superior to placebo in patients with non-ST-elevation acute coronary syndromes receiving aspirin. The purpose of the present analysis was to estimate the treatment effect Zof clopidogrel in patients who were stratified according to their risk of future cardiovascular events.
METHODS AND RESULTS: Patients (n=12 562) who presented within 24 hours after the onset of symptoms were randomized to receive clopidogrel (300 mg followed by 75 mg daily) or placebo in addition to aspirin for 3 to 12 months. Treatment effect was analyzed in various risk groups according to the Thrombolysis in Myocardial Infarction (TIMI) risk score. The TIMI risk model was validated in the CURE population (C statistic， 0.634). The primary composite outcome of cardiovascular death， myocardial infarction， or stroke increased proportionally with increasing risk according to the TIMI risk score. The impact of clopidogrel versus placebo on the rate of the primary outcome was as follows: low-risk group (TIMI score 0 to 2)， 4.1% versus 5.7% (relative risk [RR]， 0.71; 95% confidence interval [CI]， 0.52 to 0.97; P< 0.04)， intermediate-risk group (TIMI score 3 to 4)， 9.8% versus 11.4% (RR， 0.85; 95% CI， 0.74 to 0.98; P<0.03)， and high-risk group (TIMI score 5 to 7)， 15.9% versus 20.7% (RR， 0.73; 95% CI， 0.60 to 0.90; P<0.004). There was no evidence of statistical heterogeneity among the groups.
CONCLUSIONS: The benefit of clopidogrel demonstrated in the CURE trial is consistent in low-， intermediate-， and high-risk patients with acute coronary syndromes (as stratified by TIMI risk score)， thus supporting its use in all patients with documented non-ST elevation acute coronary syndromes.